Baxter International (NYSE:BAX – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it compare to its rivals? We will compare Baxter International to related businesses based on the strength of its profitability, analyst recommendations, earnings, institutional ownership, dividends, valuation and risk.
Profitability
This table compares Baxter International and its rivals’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Baxter International | -6.23% | 16.23% | 5.08% |
| Baxter International Competitors | -270.28% | -155.47% | -22.38% |
Dividends
Baxter International pays an annual dividend of $0.04 per share and has a dividend yield of 0.2%. Baxter International pays out -2.8% of its earnings in the form of a dividend. As a group, “Healthcare Equipment & Supplies” companies pay a dividend yield of 2.1% and pay out 47.3% of their earnings in the form of a dividend.
Analyst Ratings
This is a breakdown of current recommendations for Baxter International and its rivals, as provided by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Baxter International | 3 | 10 | 1 | 0 | 1.86 |
| Baxter International Competitors | 4311 | 10598 | 18388 | 838 | 2.46 |
Baxter International currently has a consensus target price of $23.27, suggesting a potential downside of 10.08%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.66%. Given Baxter International’s rivals stronger consensus rating and higher possible upside, analysts plainly believe Baxter International has less favorable growth aspects than its rivals.
Earnings and Valuation
This table compares Baxter International and its rivals gross revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Baxter International | $11.61 billion | -$957.00 million | -18.36 |
| Baxter International Competitors | $1.89 billion | $135.83 million | 5.76 |
Baxter International has higher revenue, but lower earnings than its rivals. Baxter International is trading at a lower price-to-earnings ratio than its rivals, indicating that it is currently more affordable than other companies in its industry.
Institutional & Insider Ownership
90.2% of Baxter International shares are held by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are held by institutional investors. 0.2% of Baxter International shares are held by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Volatility and Risk
Baxter International has a beta of 0.68, meaning that its share price is 32% less volatile than the S&P 500. Comparatively, Baxter International’s rivals have a beta of 2.58, meaning that their average share price is 158% more volatile than the S&P 500.
Summary
Baxter International rivals beat Baxter International on 9 of the 15 factors compared.
Baxter International Company Profile
Baxter International is a global healthcare company that develops and supplies products used in hospitals, clinics and other care settings. Its offerings include intravenous solutions and administration sets, infusion pumps, medication-delivery systems, and products for surgical and hospital care. The company also provides patient-monitoring and connected-care technologies, including products associated with Hillrom, which Baxter acquired in 2021. Its products and services support healthcare professionals and patients in countries around the world.
Receive News & Ratings for Baxter International Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Baxter International and related companies with MarketBeat.com's FREE daily email newsletter.
